Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Ratings
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The group's high margin levels account for strong profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at GBX 7970.
  • Technically, the stock approaches a strong medium-term resistance at GBX 8317.
  • The company's enterprise value to sales, at 3.63 times its current sales, is high.
  • The firm trades with high earnings multiples: 23.2 times its 2021 earnings per share.
  • Below the resistance at 7970 GBX, the stock shows a negative configuration when looking looking at the weekly chart.
Ratings chart
Sector Other Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
ASTRAZENECA PLC7.37%145 472
JOHNSON & JOHNSON8.16%448 257
ROCHE HOLDING AG-1.80%290 657
PFIZER, INC.8.72%224 020
ABBVIE INC.8.66%205 641
NOVARTIS AG-3.78%200 099
MERCK & CO., INC.-4.29%198 235
NOVO NORDISK A/S12.23%179 620
ELI LILLY AND COMPANY16.21%178 360
BRISTOL-MYERS SQUIBB COMPAN..4.59%144 867
AMGEN INC.9.33%144 431
SANOFI10.19%131 645
GLAXOSMITHKLINE PLC2.12%96 628
JIANGSU HENGRUI MEDICINE CO..-24.79%69 138
BAYER AG18.49%68 039
ALLERGAN PLC0.97%63 659
More Results
Financials (USD)
Sales 2021 31 079 M - -
Net income 2021 4 531 M - -
Net Debt 2021 10 883 M - -
P/E ratio 2021 32,2x
Yield 2021 2,57%
Capitalization 146 B 146 B -
EV / Sales 2021 5,05x
EV / Sales 2022 4,48x
Nbr of Employees 76 100
Free-Float 95,7%
Upcoming event on ASTRAZENECA PLC
Surperformance Ratings©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes